Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@arnold2008] |-----------|-------| | Protein Name | Sodium/Glutamate Transporter 1 | | Gene Symbol | SLC1A1 | | UniProt ID | [P43005](https://www.uniprot.org/uniprot/P43005) | | NCBI Gene ID | [6507](https://www.ncbi.nlm.nih.gov/gene/6507) | | Protein Family | SLC1 family (EAAT) | | Molecular Weight | ~57 kDa | | Subcellular Location | Plasma membrane | | Expression | Brain, kidney, intestine |
</div>}
Overview
SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.
Molecular Function
Transport Mechanism
Sodium coupling - 3 Na+ ions per glutamate
Proton coupling - 1 H+ cotransport
Counter-transport - 1 K+ counter-transport
Electrogenic - Net positive charge transport
Substrate Specificity
Glutamate - Primary substrate
Aspartate - Alternative substrate
Cystine - In exchange for glutamate (system Xc-)
Disease Associations
Neurological Disorders
Epilepsy
...
slc1a1 Protein
Introduction
Slc1A1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [@arnold2008] |-----------|-------| | Protein Name | Sodium/Glutamate Transporter 1 | | Gene Symbol | SLC1A1 | | UniProt ID | [P43005](https://www.uniprot.org/uniprot/P43005) | | NCBI Gene ID | [6507](https://www.ncbi.nlm.nih.gov/gene/6507) | | Protein Family | SLC1 family (EAAT) | | Molecular Weight | ~57 kDa | | Subcellular Location | Plasma membrane | | Expression | Brain, kidney, intestine |
</div>}
Overview
SLC1A1 (Sodium/Glutamate Transporter 1), also known as EAAT3 (Excitatory Amino Acid Transporter 3), is a high-affinity glutamate transporter responsible for clearing excitatory neurotransmitters from the synaptic cleft. This protein plays crucial roles in preventing excitotoxicity and maintaining glutamate homeostasis in the brain.
Molecular Function
Transport Mechanism
Sodium coupling - 3 Na+ ions per glutamate
Proton coupling - 1 H+ cotransport
Counter-transport - 1 K+ counter-transport
Electrogenic - Net positive charge transport
Substrate Specificity
Glutamate - Primary substrate
Aspartate - Alternative substrate
Cystine - In exchange for glutamate (system Xc-)
Disease Associations
Neurological Disorders
Epilepsy
Glutamate clearance - Impaired in epileptic tissue
Excitotoxicity - Contributes to seizure progression
Therapeutic targeting - Modulators under investigation
PMID: 7502583(https://pubmed.ncbi.nlm.nih.gov/7502583/) - EAAT3 cloning and characterization
PMID: 10559285(https://pubmed.ncbi.nlm.nih.gov/10559285/) - EAAT3 in epilepsy
PMID: 18515852(https://pubmed.ncbi.nlm.nih.gov/18515852/) - SLC1A1 and OCD
Therapeutic Implications
Drug Development Targets
SLC1A3 (EAAT1) represents a promising therapeutic target for multiple neurological conditions. The transporter's role in glutamate homeostasis makes it an attractive target for modulating excitotoxicity.
Transport across the [BBB](/entities/blood-brain-barrier) remains a challenge for EAAT1-targeted drugs. Novel delivery approaches include:
Receptor-mediated transcytosis
Nanoparticle delivery systems
Intranasal administration
Research Directions
Biomarker Potential
EAAT1 expression patterns may serve as biomarkers for:
Glial activation in neuroinflammation
Disease progression in MS
Treatment response in epilepsy
Genetic Variants
Several SNPs in SLC1A3 have been associated with:
Migraine susceptibility
Epilepsy risk
ALS progression
Background
The study of Slc1A1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Kanai Y, Hediger MA, Primary structure and functional characterization of a high-affinity glutamate transporter (1992)](https://pubmed.ncbi.nlm.nih.gov/7502583/)
[Proper EA, Oestreicher AB, Jansen GH, et al, Immunohistochemical characterization of excitatory amino acid transporters in the human hippocampus (2000)](https://pubmed.ncbi.nlm.nih.gov/10559285/)
[Arnold PD, Sicard T, Burroughs E, et al, Glutamate system genes associated with OCD (2008)](https://pubmed.ncbi.nlm.nih.gov/18515852/)